Advances in molecular biology have made possible the production of highly purified
recombinant human proteins, and recombinant human growth factors have emerged as
potential therapeutic wound healing agents. Becaplermin (recombinant human platelet-
derived growth factor-BB [rhPDGF-BB]) quickly emerged as one of the leading candidates
for clinical trials. Before the expected therapeutic potential of rhPDGF-BB and other growth
factors could be realized, a number of concerns had to be addressed (eg, would growth …